Ajanta Pharma Ltd

Ajanta Pharma Ltd | Sector: Pharmaceuticals | ISIN: INE031B01049

₹ 1,229.90 (0.75%) icon

23 Mar, 2023, 3:49:47 PM
Open
₹ 1,223.00
Prev. Close
₹ 1,220.80
Turnover(lac)
₹ 800.91
Day's High
₹ 1,235.00
Day's Low
₹ 1,212.20
52 Wk High
₹ 1,427.50
52 Wk Low
₹ 1,061.77
Book Value
₹ 281.80
Face Value
₹ 2.00
Mkt. Cap (Cr.)
₹ 15,758.11
P/E
27.36
EPS
44.98
Div. Yield
0.52

KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 3/23/2023 3:49:47 PM

    ₹ 1229.9 9.10 0.75
  • Open
  • ₹ 1,223
  • Prev. Close
  • ₹ 1,220.8
  • Turnover(Lac.)
  • ₹ 801
  • Day's High
  • ₹ 1,235
  • Day's Low
  • ₹ 1,212.2
  • 52 Week's High
  • ₹ 1,427.5
  • 52 Week's Low
  • ₹ 1,061.77
  • Book Value
  • ₹ 281.8
  • Face Value
  • ₹ 2
  • Mkt Cap (₹ Cr.)
  • 15,758.11
  • P/E
  • 27.36
  • EPS
  • 44.98
  • Divi. Yield
  • 0.52

Corporate Actions

06 Mar , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

23 Jan , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

23 Jan , 2023

12:00 AM

03 Nov , 2022

12:00 AM

Dividend

Dividend amount: 7
Announcement date: 03 Nov , 2022

View Details

21 Oct , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

21 Oct , 2022

12:00 AM

21 Jun , 2022

12:00 AM

AGM

Announcement date: 21 Jun , 2022

View Details

20 Jul , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

20 Jul , 2022

12:00 AM

13 Jun , 2022

12:00 AM

02 May , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

02 May , 2022

12:00 AM


SHAREHOLDING SNAPSHOT
24 March , 2023 | 07:57 AM

PROMOTER - TOTAL66.11%

Indian: 66.11%

Foreign: 0%

NON-PROMOTER - TOTAL 33.89%

Institutions: 25.90%

Non-Institutions: 8.00%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Ajanta Pharma Ltd News and Update

Article Image
  • 19 hours ago |
  • 4:02 PM

Acquisition done for Rs 18.45 crore.

Article Image
Article Image
  • IIFL News Service |
  • 22 hours ago |
  • 4:02 PM
ad IconAd Image

FINANCIALS

PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Ajanta Pharma Ltd

  • Mannalal B Agrawal

  • Chairman
  • Madhusudan B Agrawal

  • Vice Chairman
  • Yogesh Agrawal

  • Managing Director
  • Chandrakanth M Khetan

  • Independent Director
  • Gaurang Shah

  • Company Secretary
  • Rajesh M Agrawal

  • Joint Managing Director
  • K H Viswanathan

  • Independent Director
  • Prabhakar Dalal

  • Independent Director
  • Anjana Grewal

  • Independent Director

Summary

Ajanta Pharma is a specialty pharmaceutical company primarily involved in development, manufacturing and marketing of marketing of quality finished dosages in domestic and international markets. It has a well-diversified business model in terms of markets, therapies and products. It produces a comprehensive range of specialty products targeting different therapeutic segments.The companys business includes Branded Generics in emerging markets of Asia and Africa, Generics in the developed markets of USA and Institution sales. The branded generics business is spread in India and more than 30 emerging countries across Africa, CIS, the Middle East and South East Asia. In India, the Company has presence in high growth specialty segments of cardiology, dermatology, ophthalmology and pain management.In branded generic business in emerging markets in Asia and Africa, Ajanta Pharmas products cater to therapeutic segments like Anti-Biotic, Anti-Malarial, Anti-Diabetic, Cardiology, Gynecology, Orthopedics, Pediatric, Respiratory & General Health products. The companys institutional business comprises of supplies to various government bodies in India and supply of Anti-Malarial products under WHO approved programs in Africa.Ajanta Pharma operates 7 state-of-the-art manufacturing facilities in India and Mauritius. 2 of the facilities in India have been successfully approved by US FDA. The company has an advanced Research & Development Centre in Mumbai for finished formulations and Active... Read More


Reports by Ajanta Pharma Ltd


Reports by Ajanta Pharma Ltd